Full-Time

Data Analytics Engineer 1 #

Posted on 7/21/2026

GRAIL

GRAIL

1,001-5,000 employees

Blood-based cancer detection via sequencing tests

Compensation Overview

$86k - $106k/yr

+ Annual Bonus + Incentives

Durham, NC, USA

Hybrid

60% on-site required; hybrid work arrangement.

Category
Data & Analytics (1)
Required Skills
Power BI
Python
R
SQL
Tableau
Excel/Numbers/Sheets

Get referred to GRAIL

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in Data Analytics, Statistics, Mathematics, Computer Science, Information Systems, Business, or related discipline with 0–2 years of relevant experience.
  • Demonstrated ability to collect, organize, and analyze data with attention to accuracy and detail.
  • Experience preparing reports, dashboards, or visualizations using Excel or introductory business intelligence tools.
  • Basic proficiency with SQL, Python, R, or comparable analytical tools.
  • Strong critical thinking and problem-solving skills in a data-driven environment.
  • Ability to communicate clearly with both technical and non-technical stakeholders.
  • Interest in learning new data analysis techniques and technologies to support business insights.
  • Demonstrated level of knowledge regarding applicable regulatory standards commensurate with the position's complexity and scope, contributing to organizational regulatory compliance.
  • GMP quality management systems (e.g. ISO 13485)
  • Clinical laboratory regulations (e.g. CAP, CLIA, NYSDOH, ISO 15189)
  • Protected health information (e.g. HIPAA, GDPR)
  • Operations within the regulated medical device environment (e.g. IVDD, IVDR, FDA 21 CFR 800 series, FDA 21 CFR Part 11)
  • Development and Operations within a regulated clinical study environment (e.g. ICH E6 (GCP), ISO 20916, FDA 21 CFR Part 11, Part 50, Part 54, Part 56)
  • Strong analytical and quantitative skills with the ability to interpret and communicate data findings clearly.
  • Proficiency with Excel and exposure to analytical tools such as SQL, Python, R, or Power BI/Tableau.
  • Basic understanding of data structures, relational databases, and data visualization principles.
Responsibilities
  • Collects, transforms, and validates data from diverse sources, applying professional analytical techniques to ensure accuracy and reliability.
  • Performs exploratory and descriptive analysis to identify trends, patterns, and key performance drivers for business stakeholders.
  • Develops and maintains reports, dashboards, and visualizations that communicate analytical findings in a clear and actionable manner.
  • Interprets data requirements, collaborates with business partners, and applies professional judgment to structure analyses that meet defined objectives.
  • Documents analytical logic, data sources, and methodologies to support transparency, reproducibility, and continuous improvement.
  • Supports cross-functional initiatives by providing data-driven insights and contributing to analytical problem-solving efforts.
  • Identifies and recommends opportunities to streamline analytical workflows, standardize reporting, or enhance data quality.
  • Builds proficiency in analytics tools, data modeling concepts, and best practices to expand analytical independence and effectiveness
Desired Qualifications
  • Attention to detail with a focus on data accuracy and integrity.
  • Ability to manage multiple priorities and meet deadlines in a fast-paced environment.
  • Effective written and verbal communication skills for presenting data insights to non-technical audiences.
  • Collaborative mindset with an eagerness to learn from experienced colleagues and contribute to team success.

GRAIL develops blood-based cancer tests that aim to detect cancer at its earliest stages. The tests use high-intensity sequencing to analyze large amounts of tumor genome data from a blood sample and apply advanced algorithms and deep learning to identify signals indicating cancer. Revenue comes from selling these tests to healthcare providers and research institutions, with potential expansion to direct-to-consumer sales in the future. Compared with others, GRAIL combines extensive sequencing data with clinical studies and sophisticated analytics to provide actionable cancer-detection results, focusing on early diagnosis. The company’s goal is to lower global cancer mortality by catching the disease early when treatment is more effective.

Company Size

1,001-5,000

Company Stage

Post IPO Equity

Headquarters

Menlo Park, California

Founded

2016

Get referred to GRAIL

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected late 2026 or early 2027 could unlock a $100 billion addressable screening market
  • Samsung C&T secured exclusive Galleri distribution in South Korea with expansion plans for Japan and Singapore
  • Revenue grew from $93 million in 2022 to $147 million in 2025 with 56,000 tests sold in Q1 2026

What critics are saying

  • NHS-Galleri trial failed its primary endpoint of reducing Stage III-IV cancers, jeopardizing FDA approval within 6–12 months
  • Two securities class actions allege management misrepresented NHS trial prospects, threatening financial stability by mid-2026
  • Insurers may reject coverage due to trial failure, collapsing revenue as most patients depend on reimbursement within 12–18 months

What makes GRAIL unique

  • Galleri detects over 50 cancer types using DNA methylation patterns and deep learning algorithms
  • The test maintains a false positive rate below 1%, lower than other multi-cancer early detection platforms
  • GRAIL leverages high-intensity sequencing and population-scale clinical trials for validated early-stage detection

Help us improve and share your feedback! Did you find this helpful?

Benefits

Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.

Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.

Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.

Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Africas SMB Journal
Jun 9th, 2026
INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in GRAIL, Inc. of class action lawsuit and upcoming deadlines - GRAL.

INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in GRAIL, Inc. of class action lawsuit and upcoming deadlines - GRAL. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. ("Grail" or the "Company") (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Grail and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 4, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Grail securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On this news, Grail's stock price fell more than 50%, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical Lab Products
May 7th, 2026
GRAIL to present new data on multi-cancer early detection test.

GRAIL to present new data on multi-cancer early detection test. Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants. GRAIL will present additional data from the NHS-Galleri trial and the PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will further evaluate the Galleri multi-cancer early detection (MCED) test during the event held May 29 to June 2, 2026, in Chicago. The NHS-Galleri trial presentation will expand on topline results announced in February 2026. As a randomized controlled study of an MCED test, it was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rates within the National Health Service (NHS) in England. The trial evaluated annual screening with the Galleri test in addition to standard of care screening over three years in more than 142,000 participants aged 50 to 77. The complete dataset from the PATHFINDER 2 study, which includes more than 32,000 evaluable participants, will also be presented. Conducted under a Food and Drug Administration (FDA)-approved investigational device exemption, PATHFINDER 2 is an MCED interventional study in North America focused on an intended-use population with no clinical suspicion of cancer. "These results from NHS-Galleri and PATHFINDER 2, two large, rigorous studies, underscore Galleri's strong performance, ability to shift detection of cancers earlier before metastatic disease, and strong safety profile," says Josh Ofman, president of GRAIL, in a release. "We look forward to sharing these findings, which strengthen the body of evidence supporting the clinical utility, performance, and safety of Galleri in intended-use populations and reflect GRAIL's extensive experience building a robust evidence base for multi-cancer early detection." Additional data will include a poster presentation on the implementation of the MCED test in private practice settings. This study examines adoption, performance, and repeat-testing patterns for the blood-based screening tool. The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. While the Galleri test is intended for clinical purposes, it has not been cleared or approved by the FDA. The test is currently recommended for adults with an elevated risk for cancer, such as those aged 50 or older, and is intended to be used in addition to routine cancer screening tests. Photo caption: Galleri test Photo credit: File/GRAIL Related Reading:

PR Newswire
Apr 10th, 2026
Junction partners with GRAIL to enable multi-cancer screening through diagnostic platform

Junction, a diagnostic testing infrastructure platform, has announced a collaboration with GRAIL to support access to the Galleri multi-cancer early detection test across digital health platforms and clinical organisations. Through Junction's infrastructure, healthcare providers can integrate Galleri into their workflows with unified ordering, embedded physician networks and streamlined operational support. The Galleri test is a blood test designed to detect signals from over 50 cancer types, many lacking recommended screening options. Junction's platform enables organisations to order the Galleri test directly, support multi-state clinical operations and manage complex testing workflows. The collaboration aims to simplify the operational steps around offering Galleri, making it easier for providers to integrate the test into care delivery. Junction provides infrastructure that powers healthcare platforms through a single API.

360Dx
Apr 7th, 2026
Grail, Epic partner to broaden Galleri MCED test ordering.

Grail, Epic partner to broaden Galleri MCED test ordering. NEW YORK - Grail on Tuesday announced a collaboration with Epic to integrate the Galleri multi-cancer early detection test into Epic's electronic health record platforms. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Mar 22nd, 2026
One Fin exits $22M GRAIL stake before 50% crash

One Fin Capital Management completely exited its position in GRAIL on 17 February 2026, selling approximately 380,000 shares worth $22.47 million. The timing proved fortuitous, as GRAIL subsequently experienced a roughly 50% single-day decline following an earnings announcement. The liquidation reduced GRAIL's weighting in the fund's portfolio from 7.4% to zero. GRAIL, a biotechnology company specialising in blood-based multi-cancer early detection, had been a strong performer with shares up 68% year-to-date prior to the crash. Despite selling over 185,000 Galleri tests and generating $147.2 million in revenue, GRAIL reported a net loss of $408.35 million. The company's current market capitalisation stands at $1.9 billion.